MedTrace Logo

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

NCT03241108 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2018-08-14

No results posted yet for this study

Summary

This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis

Conditions

Interventions

DRUG

NI-0101

Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Light Chain Bioscience - Novimmune SA

    lead INDUSTRY

Principal Investigators

  • Ernest Choy, MD · Institute of Infection and Immunity, Cardiff University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-10
Primary Completion
2018-06-20
Completion
2018-06-20

Countries

  • Bosnia and Herzegovina
  • Bulgaria
  • Georgia
  • Hungary
  • Moldova
  • Poland
  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03241108 on ClinicalTrials.gov